Scarica l'app Stockscreener
22.67
0.13%
0.03
Oculis Holding Ag Borsa (OCS) Ultime notizie
Oculis Announces Significant Voting Rights Changes Following Íslandsbanki Activity - StockTitan
Oculis Is An Interesting Growth Bet On Non-Invasive Eye Care (NASDAQ:OCS) - Seeking Alpha
Oculis Announces Major Voting Rights Changes Involving Íslandsbanki in Switzerland - StockTitan
(OCS) Proactive Strategies - Stock Traders Daily
Oculis (NASDAQ:OCS) Reaches New 12-Month HighTime to Buy? - MarketBeat
Here's What Could Help Oculis Holding AG (OCS) Maintain Its Recent Price Strength - MSN
Oculis (NASDAQ:OCS) Shares Gap Up – Here’s Why - Defense World
Head to Head Comparison: Oculis (NASDAQ:OCS) vs. Immunome (NASDAQ:IMNM) - Defense World
Accure Therapeutics partner Oculis reached positive phase 2 results for lead neuroprotective therapy - MENAFN.COM
Oculis (NASDAQ:OCS) Shares Gap UpWhat's Next? - MarketBeat
Trading (OCS) With Integrated Risk Controls - Stock Traders Daily
Chardan Capital Reiterates Buy Rating for Oculis (NASDAQ:OCS) - Defense World
Oculis (NASDAQ:OCS) Sees Large Volume IncreaseHere's Why - MarketBeat
HC Wainwright Reaffirms “Buy” Rating for Oculis (NASDAQ:OCS) - Defense World
Oculis' (OCS) "Buy" Rating Reiterated at Chardan Capital - MarketBeat
Oculis reiterates shares target, buy rating post-trial - Investing.com
Stifel maintains Oculis stock Buy rating, $35 target post-study - Investing.com India
Oculis Trial Shows Potential for Optical Neuroprotective Therapy - Yahoo Finance
Oculis Holding’s OCS-05 Shows Promising Results in Phase 2 Trial for Acute Optic Neuritis - TipRanks
Stifel maintains Oculis stock Buy rating, $35 target post-study By Investing.com - Investing.com South Africa
Oculis' (OCS) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Oculis presents 'groundbreaking' data in optic neuritis with OCS-05 - BioWorld Online
Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential... - Markets Insider
OCSOculis Holding AG Ordinary shares Latest Stock News & Market Updates - StockTitan
Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy - The Manila Times
Oculis' OCS-05 Shows Breakthrough 43% Vision Improvement in Phase 2 Optic Neuritis Trial - StockTitan
Oculis Phase 2 Trial Shows 43% Vision Improvement in Optic Neuritis Treatment Breakthrough - StockTitan
Oculis Publishes Notification of Major Changes in Voting Rights - 24matins.uk
Oculis Holding Announces Major Voting Rights Restructure as Key Shareholder Redistributes Stakes - StockTitan
Oculis Holding (OCS): A Biopharma Opportunity for Adventurous Investors - TipRanks
(OCS) Investment Analysis and Advice - Stock Traders Daily
Oculis (NASDAQ:OCS) Sees Unusually-High Trading Volume – Here’s Why - Defense World
Oculis (NASDAQ:OCS) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
(OCS) Investment Report - Stock Traders Daily
Oculis Directors Complete RSU Vesting Transaction in Strategic Stock Move - StockTitan
Oculis Holding AG (NASDAQ:OCS) Short Interest Update - MarketBeat
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated - Marketscreener.com
Oculis Announces Major Share Vesting Event for Key Executives | OCS Stock News - StockTitan
Where are the Opportunities in (OCS) - Stock Traders Daily
Oculis Publishes Notification of Transaction by Person Discharging Managerial Responsibilities - Marketscreener.com
Oculis Awards Equity Incentive to Director Arshad Khanani for Consulting Services | OCS Stock News - StockTitan
Oculis (NASDAQ:OCS) Shares Up 3.8%Here's Why - MarketBeat
(OCS) Investment Analysis - Stock Traders Daily
Is Oculis Holding (OCS) Top Performing European Stock Heading into 2025? - Insider Monkey
Oculis to Present at the Stifel 2024 Healthcare Conference - The Manila Times
Oculis (OCS) to Present at Stifel Healthcare Conference: CFO Fireside Chat Announced | OCS Stock News - StockTitan
10 Top Performing European Stocks Heading into 2025 - Insider Monkey
HC Wainwright Reiterates Buy Rating for Oculis (NASDAQ:OCS) - MarketBeat
Oculis Holding AG Reports Q3 2024 Financial Progress - TipRanks
Oculis Holding’s Financial Struggles Amid Asset Growth - TipRanks
Oculis Holding AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
0.98%
7.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):